Myriad data.
Individual care.



How do you fast-track and improve the efficacy of novel treatments and therapies? How do you provide deeper, more effective care?

By developing technology-powered health services that elevate clinical care and deliver deeper clinical insights. By learning from every patient. By testing and validating novel treatments in the real world. In real time. By collecting and systematising live, dynamic, multidimensional patient data and clinical evidence. By making patients part of the clinical research journey and clinical innovation part of every patient’s health journey. Welcome to Emyria and evidence-generating care.

We Are

Caring. Curious. Courageous.



We’re bringing together patients, clinicians, researchers and medical innovators to develop novel treatments and combine conventional ones in new ways.

To dive deeper into each patient’s case, especially patients who have run out of options. To deliver a greater depth of clinical care. To think more deeply and innovatively about helping people thrive and live happier, healthier lives.


We’re pioneering new methodologies and technologies to collect, standardise and systematise live, dynamic patient data and clinical evidence.

To discover insights previously hidden from view. To test, validate and develop novel treatments and therapies. In the real world. In collaboration with our clinicians, patients and clinical evidence specialists.


A global network of clinicians, patients, researchers and innovators coming together to advance medical knowledge and science. To transform health outcomes for every patient.
To benefit humanity.


Helping organisations manage COVID and get back to business.

Our clinician-led COVID-19 remote screening, triage and monitoring platform helps organisations, clinicians and researchers understand COVID-19 symptoms, clinical signs and other risk factors. Our aim: to proactively manage the COVID pandemic, reduce the strain on health systems, learn more about this new disease and enable organisations to get back to business. Find out how we’re fighting COVID-19 with live, dynamic real-world evidence (RWE).
COVID-19 infections in over 185 countries
Estimated global cost: More than USD 5.8 trillion
Openly: A wellness screening service, powered by your smartphone and backed by a clinical team
Actionable risk-management insights


Testing and validating cannabinoids using live, real-world patient data.

There’s a lot of anecdotal support for cannabinoid-based medicines (CBMs), but a dearth of high-quality, product-specific clinical evidence. Our clinicians at our purpose-built clinics are providing evidence-generating care for patients, using our dynamic approach to patient data capture to monitor and validate CBMs in the real world and generate regulator-grade evidence.
More than 1,000 data points per patient
More than 2,000 patients to date
Real world evidence (RWE) market worth USD $1.64 billion by 2024
47% of FDA approvals incorporate real-world evidence and growing


Improving treatments for chronic pain with multidimensional RWE.

GP clinic Maritime Health has been using our research platform to manage, monitor and improve the safety and efficacy of novel treatments for chronic pain. The practice is also using our platform to generate dynamic patient data to improve treatments for a range of other debilitating and costly health issues, including mental health, sleep, addiction and musculoskeletal conditions and problems.
One in five live with chronic pain
That’s ~1.5 billion people globally
In the US alone, chronic pain costs the economy US$600 billion annually

We see a global opportunity and believe that much of what we want to achieve today is already possible by bringing together the right talent and technology and staying caring, curious and courageous.


Ours is a collaborative vision and venture. We’re bringing people and partners together for the greater good: patients, clinicians, researchers, medical innovators and, of course, investors.

If, like us, you’re inspired by the almost limitless humanitarian and commercial potential of our evidence-generating clinical care, here’s where you can find out more about Emyria.
47.2 %
FDA approvals where real-world evidence (RWE) was provided, and growing.
1000 +
Unique data points collected per patient.
$ 3 T USD
Trillion USD cost of chronic disease and mental health per year in the US.
Call 1300 436 363Contact